Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 64132
Gene Symbol: XYLT2
XYLT2
0.300 Biomarker disease GENOMICS_ENGLAND
Entrez Id: 2355
Gene Symbol: FOSL2
FOSL2
0.300 Biomarker disease MGD
Entrez Id: 2313
Gene Symbol: FLI1
FLI1
0.300 Biomarker disease MGD
Entrez Id: 7046
Gene Symbol: TGFBR1
TGFBR1
0.250 Biomarker disease MGD
Entrez Id: 5053
Gene Symbol: PAH
PAH
0.170 Biomarker disease HPO
Entrez Id: 4000
Gene Symbol: LMNA
LMNA
0.120 Biomarker disease HPO
Entrez Id: 7486
Gene Symbol: WRN
WRN
0.110 Biomarker disease HPO
Entrez Id: 3930
Gene Symbol: LBR
LBR
0.110 Biomarker disease HPO
Entrez Id: 7389
Gene Symbol: UROD
UROD
0.100 Biomarker disease HPO
Entrez Id: 23592
Gene Symbol: LEMD3
LEMD3
0.100 Biomarker disease HPO
Entrez Id: 5424
Gene Symbol: POLD1
POLD1
0.100 Biomarker disease HPO
Entrez Id: 6559
Gene Symbol: SLC12A3
SLC12A3
0.100 Biomarker disease HPO
Entrez Id: 1188
Gene Symbol: CLCNKB
CLCNKB
0.100 Biomarker disease HPO
Entrez Id: 7390
Gene Symbol: UROS
UROS
0.100 Biomarker disease HPO
Entrez Id: 3077
Gene Symbol: HFE
HFE
0.100 Biomarker disease HPO
Entrez Id: 55315
Gene Symbol: SLC29A3
SLC29A3
0.100 Biomarker disease HPO
Entrez Id: 49
Gene Symbol: ACR
ACR
0.100 Biomarker disease BEFREE <b>Methods:</b> Limited (lSSc, <i>n</i> = 76) and diffuse SSc (dSSc, <i>n</i> = 41) fulfilling the ACR/EULAR 1980 and 2013 classification criteria for SSc and asymptomatic controls (<i>n</i> = 9) were included. 30821519 2019
Entrez Id: 8654
Gene Symbol: PDE5A
PDE5A
0.020 GeneticVariation disease BEFREE <b>Objectives:</b> The usage of oral therapies, endothelin receptor antagonists (ERA), phosphodiesterase type-5 (PDE-5) inhibitors and prostaglandin analogues has resulted in improved outcomes in patients with pulmonary arterial hypertension related to systemic sclerosis (SSc-PAH). 31829087 2020
Entrez Id: 7124
Gene Symbol: TNF
TNF
0.100 Biomarker disease BEFREE <b>Objectives:</b> We explored the interactions of osteoprotegerin (OPG) with biomarkers of bone turnover and cytokines, including soluble receptor activator for nuclear factor kappa beta ligand (sRANKL), tumor necrosis factor-related apoptosis-induced ligand (TRAIL), and Wnt inhibitors in osteoporosis, vasculopathy and fibrosis related to systemic sclerosis (SSc). 30001654 2019
Entrez Id: 5027
Gene Symbol: P2RX7
P2RX7
0.010 Biomarker disease BEFREE <b>Results:</b> P2X7R expression and Ca<sup>2+</sup> permeability induced by the selective P2X7R agonist 2'-3'-O-(4-benzoylbenzoyl)ATP (BzATP) were markedly higher in SSc than control fibroblasts. 28955239 2017
Entrez Id: 7431
Gene Symbol: VIM
VIM
0.010 AlteredExpression disease BEFREE <b>Results:</b> VICM and BGM levels were increased in early compared with late dSSc (<i>p</i>< =0.023). 30457356 2019
Entrez Id: 23205
Gene Symbol: ACSBG1
ACSBG1
0.010 AlteredExpression disease BEFREE <b>Results:</b> VICM and BGM levels were increased in early compared with late dSSc (<i>p</i>< =0.023). 30457356 2019
Entrez Id: 3447
Gene Symbol: IFNA13
IFNA13
0.090 AlteredExpression disease BEFREE .To examine whether myxovirus-resistance protein A (MxA) mRNA expression, commonly considered a reliable marker of Type I interferon (IFN) bioactivity, is modified in patients with systemic sclerosis (SSc); if it is associated to specific clinical features; and if its modulation is accompanied by modulation of mRNA for the Type I IFN receptor (IFNAR). 18843779 2008
Entrez Id: 3439
Gene Symbol: IFNA1
IFNA1
0.090 AlteredExpression disease BEFREE .To examine whether myxovirus-resistance protein A (MxA) mRNA expression, commonly considered a reliable marker of Type I interferon (IFN) bioactivity, is modified in patients with systemic sclerosis (SSc); if it is associated to specific clinical features; and if its modulation is accompanied by modulation of mRNA for the Type I IFN receptor (IFNAR). 18843779 2008
Entrez Id: 3596
Gene Symbol: IL13
IL13
0.100 AlteredExpression disease BEFREE 14-3-3z sequesters cytosolic T-bet, upregulating IL-13 levels in T<sub>C</sub>2 and CD8<sup>+</sup> lymphocytes from patients with scleroderma. 29155097 2018